Literature DB >> 22213261

Serve the people or close the sale? Profit-driven overuse of injections and infusions in China's market-based healthcare system.

Lucy Reynolds1, Martin McKee.   

Abstract

Treatment by injection or infusion is widespread in China. Using the common cold as a tracer condition, we explored the reasons for over-prescription of injections and infusions in Guizhou, China. Interviews with prescribers, patients and key informants were supplemented by focus groups. These revealed how historical ideas encourage unnecessary use of percutaneous treatment: faith in the healing power of needles is locally attributed to association with acupuncture. Many patients and some staff believe that injections per se are therapeutic. However, the structure of health service financing and remuneration now reinforces this irrational faith. Market-based reforms have attempted to control costs and increase productivity with an incentive scheme which rewards prescribers financially for over-prescription in general and for use of injections and infusions in particular. Aggressive marketing has displaced oral treatment from health facilities into independent pharmacies, leaving doctors functioning mainly as injection providers. There is a need for a multi-faceted response encompassing education and reform of financial incentives to reduce the use of unnecessary treatment.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 22213261     DOI: 10.1002/hpm.1112

Source DB:  PubMed          Journal:  Int J Health Plann Manage        ISSN: 0749-6753


  31 in total

Review 1.  Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review.

Authors:  Bonny Parkinson; Catherine Sermet; Fiona Clement; Steffan Crausaz; Brian Godman; Sarah Garner; Moni Choudhury; Sallie-Anne Pearson; Rosalie Viney; Ruth Lopert; Adam G Elshaug
Journal:  Pharmacoeconomics       Date:  2015-09       Impact factor: 4.981

Review 2.  Overuse of intravenous infusions in China: focusing on management platform and cultural problems.

Authors:  Shuangshuang Zeng; Dong Wang; Wanli Liu; Yuanliang Yan; Minwen Zhu; Zhicheng Gong; Shusen Sun
Journal:  Int J Clin Pharm       Date:  2019-08-30

3.  Indigenous HIV Prevention Beliefs and Practices Among Low-Earning Chinese Sex Workers as Context for Introducing Female Condoms and Other Novel Prevention Options.

Authors:  Jennifer Dunn; Qingning Zhang; Margaret R Weeks; Jianghong Li; Susu Liao; Fei Li
Journal:  Qual Health Res       Date:  2016-11-02

4.  Profit considerations in vaccine safety-related events in China.

Authors:  Jianlin Zhuang; Yihan Lu; Abram L Wagner; Qingwu Jiang
Journal:  Expert Rev Vaccines       Date:  2019-11-13       Impact factor: 5.217

5.  The political economy of healthcare reform in China: negotiating public and private.

Authors:  Arthur Daemmrich
Journal:  Springerplus       Date:  2013-09-10

Review 6.  Systematic review on irrational use of medicines in China and Vietnam.

Authors:  Wenhui Mao; Huyen Vu; Zening Xie; Wen Chen; Shenglan Tang
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

7.  Public reporting as a prescriptions quality improvement measure in primary care settings in China: variations in effects associated with diagnoses.

Authors:  Yuqing Tang; Chaojie Liu; Xinping Zhang
Journal:  Sci Rep       Date:  2016-12-20       Impact factor: 4.379

8.  Challenges in maintaining medicine quality while aiming for universal health coverage: a qualitative analysis from Indonesia.

Authors:  Amalia Hasnida; Maarten Olivier Kok; Elizabeth Pisani
Journal:  BMJ Glob Health       Date:  2021-05

9.  Urban-rural inequality regarding drug prescriptions in primary care facilities - a pre-post comparison of the National Essential Medicines Scheme of China.

Authors:  Qiang Yao; Chaojie Liu; J Adamm Ferrier; Zhiyong Liu; Ju Sun
Journal:  Int J Equity Health       Date:  2015-07-30

10.  Editorial: Role of Health Economic Data in Policy Making and Reimbursement of New Medical Technologies.

Authors:  Mihajlo Jakovljevic; Tetsuji Yamada
Journal:  Front Pharmacol       Date:  2017-09-21       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.